Castle Biosciences, Inc. (CSTL)
NASDAQ: CSTL · Real-Time Price · USD
38.65
-0.97 (-2.45%)
At close: Dec 5, 2025, 4:00 PM EST
38.64
-0.01 (-0.03%)
After-hours: Dec 5, 2025, 5:01 PM EST
Castle Biosciences Stock Forecast
Stock Price Forecast
The 6 analysts with 12-month price forecasts for Castle Biosciences stock have an average target of 38.67, with a low estimate of 35 and a high estimate of 41. The average target predicts an increase of 0.05% from the current stock price of 38.65.
Analyst Consensus: Strong Buy
* Price targets were last updated on Nov 5, 2025.
Analyst Ratings
The average analyst rating for Castle Biosciences stock from 6 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Jun '25 | Jul '25 | Aug '25 | Sep '25 | Oct '25 | Nov '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 2 | 2 | 2 | 2 | 2 | 3 |
| Buy | 4 | 4 | 4 | 4 | 4 | 3 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 6 | 6 | 6 | 6 | 6 | 6 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| BTIG | BTIG | Strong Buy Maintains $32 → $38 | Strong Buy | Maintains | $32 → $38 | -1.68% | Nov 5, 2025 |
| Baird | Baird | Buy Maintains $39 → $41 | Buy | Maintains | $39 → $41 | +6.08% | Nov 4, 2025 |
| Canaccord Genuity | Canaccord Genuity | Strong Buy Maintains $37 | Strong Buy | Maintains | $37 | -4.27% | Sep 9, 2025 |
| Scotiabank | Scotiabank | Buy Maintains $44 → $40 | Buy | Maintains | $44 → $40 | +3.49% | May 21, 2025 |
| Lake Street | Lake Street | Strong Buy Maintains $40 → $35 | Strong Buy | Maintains | $40 → $35 | -9.44% | May 6, 2025 |
Financial Forecast
Revenue This Year
337.68M
from 332.07M
Increased by 1.69%
Revenue Next Year
334.63M
from 337.68M
Decreased by -0.90%
EPS This Year
-1.15
from 0.62
EPS Next Year
-1.45
from -1.15
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | 351.0M | 349.7M | ||||
| Avg | 337.7M | 334.6M | ||||
| Low | 311.6M | 313.3M |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | 5.7% | 3.5% | ||||
| Avg | 1.7% | -0.9% | ||||
| Low | -6.2% | -7.2% |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | -1.11 | -1.07 | ||||
| Avg | -1.15 | -1.45 | ||||
| Low | -1.20 | -2.01 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | - | - | ||||
| Avg | - | - | ||||
| Low | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.